BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 34833353)

  • 21. New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy.
    Valent P; Akin C; Sperr WR; Horny HP; Arock M; Metcalfe DD; Galli SJ
    Annu Rev Pathol; 2023 Jan; 18():361-386. PubMed ID: 36270293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2011 Apr; 86(4):362-71. PubMed ID: 21442641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
    Pardanani A; Reichard K; Tefferi A
    Br J Haematol; 2024 Feb; 204(2):402-414. PubMed ID: 38054381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child.
    Zheng Y; Nong L; Liang L; Wang W; Li T
    Diagn Pathol; 2018 Feb; 13(1):14. PubMed ID: 29458385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
    Reiter A; George TI; Gotlib J
    Blood; 2020 Apr; 135(16):1365-1376. PubMed ID: 32106312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KIT Mutations and Other Genetic Defects in Mastocytosis: Implications for Disease Pathology and Targeted Therapies.
    Chantran Y; Valent P; Arock M
    Immunol Allergy Clin North Am; 2023 Nov; 43(4):651-664. PubMed ID: 37758404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic mastocytosis.
    Ozdemir D; Dagdelen S; Erbas T
    Am J Med Sci; 2011 Nov; 342(5):409-15. PubMed ID: 21629042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event.
    Jawhar M; Schwaab J; Schnittger S; Sotlar K; Horny HP; Metzgeroth G; Müller N; Schneider S; Naumann N; Walz C; Haferlach T; Valent P; Hofmann WK; Cross NC; Fabarius A; Reiter A
    Leukemia; 2015 May; 29(5):1115-22. PubMed ID: 25567135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice.
    Valent P; Hartmann K; Schwaab J; Alvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Carter MC; Hoermann G; Sperr WR; Butterfield JH; Ustun C; Zanotti R; Radia DH; Castells M; Triggiani M; Schwartz LB; Orfao A; George TI; Sotlar K; Gotlib J; Reiter A; Horny HP; Arock M; Akin C; Metcalfe DD
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1999-2012.e6. PubMed ID: 35342031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis.
    Nedoszytko B; Arock M; Lyons JJ; Bachelot G; Schwartz LB; Reiter A; Jawhar M; Schwaab J; Lange M; Greiner G; Hoermann G; Niedoszytko M; Metcalfe DD; Valent P
    Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33401724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
    Shomali W; Gotlib J
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis.
    Reichard KK; Chen D; Pardanani A; McClure RF; Howard MT; Kurtin PJ; Wood AJ; Ketterling RP; King RL; He R; Morice WG; Hanson CA
    Am J Clin Pathol; 2015 Sep; 144(3):493-502. PubMed ID: 26276780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic Mastocytosis: Advances in Diagnosis and Current Management.
    Pullarkat ST; Wu W; Pullarkat V
    Cancer Treat Res; 2021; 181():167-178. PubMed ID: 34626361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mastocytosis: from a Molecular Point of View.
    Komi DEA; Rambasek T; Wöhrl S
    Clin Rev Allergy Immunol; 2018 Jun; 54(3):397-411. PubMed ID: 28725969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
    Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
    Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel approaches to treating advanced systemic mastocytosis.
    Gilreath JA; Tchertanov L; Deininger MW
    Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.
    Gotlib J; Schwaab J; Shomali W; George TI; Radia DH; Castells M; Carter MC; Hartmann K; Álvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Hoermann G; Sperr WR; Elberink HO; Siebenhaar F; Butterfield JH; Ustun C; Zanotti R; Triggiani M; Schwartz LB; Lyons JJ; Orfao A; Sotlar K; Horny HP; Arock M; Metcalfe DD; Akin C; Lübke J; Valent P; Reiter A
    J Allergy Clin Immunol Pract; 2022 Aug; 10(8):2025-2038.e1. PubMed ID: 35724948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022.
    Arock M; Hoermann G; Sotlar K; Hermine O; Sperr WR; Hartmann K; Brockow K; Akin C; Triggiani M; Broesby-Olsen S; Reiter A; Gotlib J; Horny HP; Orfao A; Metcalfe DD; Valent P
    J Allergy Clin Immunol; 2022 Jun; 149(6):1855-1865. PubMed ID: 35430191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of Avapritinib for the Treatment of Systemic Mastocytosis.
    Sumbly V; Landry I; Iqbal S; Bhatti Z; Alshamam MS; Ashfaq S; Rizzo V
    Cureus; 2021 Sep; 13(9):e18385. PubMed ID: 34729266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
    Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
    J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.